Version 1
: Received: 7 June 2023 / Approved: 8 June 2023 / Online: 8 June 2023 (10:36:45 CEST)
How to cite:
Alfaraj, R.; Eltayb, E. K.; AlFayez, B. M.; Abohamad, A. S.; Eltaher, E.; Alenazi, N. A.; Hababah, S.; Alkahtani, H. M.; Almangour, T. A.; Alqahtani, F. Y.; Aleanizy, F. S. Studying Anti-virulence Activity of Meta-Bromo-Thiolactone against Staphylococcus aureus and MRSA Phenotypes. Preprints2023, 2023060628. https://doi.org/10.20944/preprints202306.0628.v1
Alfaraj, R.; Eltayb, E. K.; AlFayez, B. M.; Abohamad, A. S.; Eltaher, E.; Alenazi, N. A.; Hababah, S.; Alkahtani, H. M.; Almangour, T. A.; Alqahtani, F. Y.; Aleanizy, F. S. Studying Anti-virulence Activity of Meta-Bromo-Thiolactone against Staphylococcus aureus and MRSA Phenotypes. Preprints 2023, 2023060628. https://doi.org/10.20944/preprints202306.0628.v1
Alfaraj, R.; Eltayb, E. K.; AlFayez, B. M.; Abohamad, A. S.; Eltaher, E.; Alenazi, N. A.; Hababah, S.; Alkahtani, H. M.; Almangour, T. A.; Alqahtani, F. Y.; Aleanizy, F. S. Studying Anti-virulence Activity of Meta-Bromo-Thiolactone against Staphylococcus aureus and MRSA Phenotypes. Preprints2023, 2023060628. https://doi.org/10.20944/preprints202306.0628.v1
APA Style
Alfaraj, R., Eltayb, E. K., AlFayez, B. M., Abohamad, A. S., Eltaher, E., Alenazi, N. A., Hababah, S., Alkahtani, H. M., Almangour, T. A., Alqahtani, F. Y., & Aleanizy, F. S. (2023). Studying Anti-virulence Activity of Meta-Bromo-Thiolactone against <em>Staphylococcus aureus</em> and MRSA Phenotypes. Preprints. https://doi.org/10.20944/preprints202306.0628.v1
Chicago/Turabian Style
Alfaraj, R., Fulwah Y Alqahtani and Fadilah Sfouq Aleanizy. 2023 "Studying Anti-virulence Activity of Meta-Bromo-Thiolactone against <em>Staphylococcus aureus</em> and MRSA Phenotypes" Preprints. https://doi.org/10.20944/preprints202306.0628.v1
Abstract
Of late, the focus has been shifted towards quorum sensing inhibitors which reduce bacterial virulence and lower the probability of resistance and refining infections. In this work, meta-bromo-thiolactone (mBTL), a potent quorum and virulence inhibitor against Staphylococcus aureus and MRSA phenotypes, was formulated in chitosan nanoparticles (ChNPs) using ionic gelation method. mBTL-loaded-ChNPs were characterized for particle size, polydispersity index, zeta potential. Morphology was visualized by Transmission Electron Microscopy (TEM), drug release profile and antibiofilm analysis using Confocal Laser Scanning Microscope (CLSM) and Scanning Electron Microscopy (SEM) were performed. Synthesized mBTL-loaded-CNPs showed homogenized nano-size particles ranging from 158+1.3 to 284+5.6 nm with spherical particles that exhibited sustainable release profile over 48 hr at 37 °C. These findings revealed successful preparation of mBTL-loaded-ChNPs, that further showed effective antibiofilm activity at MIC50 (0.5 mg/mL) where all strains displayed reduced biofilm formation compared to untreated strains. CLSM results showed a significant reduction in the number of viable cells, indicating the effectiveness of m-BTL as an antibacterial agent. SEM analysis permitted visualization of biofilm structure in relation to the spatial localization of important biofilm matrix components, the formed biofilms were clearly distinguished in the SEM images. Bacterial cells in the control group were enclosed in thick biofilms. In contrast, there was a considerable reduction in biofilm production when mBTL was present, where bacterial cells seemed less ordered and more scattered with no detectable biofilms. In conclusion, mBTL-loaded-ChNPs is a potential alternative treatment to overcome antimicrobial resistance and condensed MRSA infections.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.